PTX3-targeted Antifungal Prophylaxis

Summary

This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute myeloid leukemia who receive induction chemotherapy. Allocation strategy based on an invasive mold infection genetic risk will be double-blinded.

Timeline

Start

2019-02-11

Primary completion

2027-11-30

Completion

2027-11-30

Drugs

Indications